This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 92/2/577    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheong, J. M. K. Articles by Weaver, C. M. Search for Related Content PubMed PubMed Citation Articles by Cheong, J. M. K. Articles by Weaver, C. M. Related Collections Calcium and Bone Metabolism Female Endocrinology

Soy Isoflavones Do Not Affect Bone Resorption in Postmenopausal Women: A Dose-Response Study Using a Novel Approach with ⁴¹Ca

Foods and Nutrition (J.M.K.C., B.R.M., C.M.W.), PRIME Lab (G.S.J., D.E.), and Statistics (G.P.M., J.R.N.), and Purdue University, West Lafayette, Indiana 47907-2059; Department of Pharmacology (S.B.), University of Alabama, Birmingham, Alabama 53294; and School of Medicine (M.P.), Indiana University, Indianapolis, Indiana 46202

Address all correspondence and requests for reprints to: Connie M. Weaver, Department of Foods and Nutrition, Purdue University, 700 West State Street, West Lafayette, Indiana 47907-2059. E-mail: weavercm{at}purdue.edu.

Introduction: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments.

Methods: Thirteen postmenopausal women (6 yr since menopause) were predosed with ⁴¹Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for ⁴¹Ca/Ca analysis by accelerator mass spectrometry.

Results: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary ⁴¹Ca/Ca ratios.

Conclusions: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary ⁴¹Ca excretion from prelabeled bone.

This article has been cited by other articles:

				S. Barnes, D. F Birt, B. R Cassileth, W. T Cefalu, F. H Chilton, N. R Farnsworth, I. Raskin, R. B van Breemen, and C. M Weaver Technologies and experimental approaches at the National Institutes of Health Botanical Research Centers Am. J. Clinical Nutrition, February 1, 2008; 87(2): 476S - 480S. [Abstract] [Full Text] [PDF]

				C. M Weaver, S. Barnes, J M. Wyss, H. Kim, D. M Morre, D J. Morre, J. E Simon, M. A. Lila, E. M Janle, and M. G Ferruzzi Botanicals for age-related diseases: from field to practice Am. J. Clinical Nutrition, February 1, 2008; 87(2): 493S - 497S. [Abstract] [Full Text] [PDF]